Liping Zuo
Union Hospital
Wuhan, 430022, China
Wuhan, 430022, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Polymerase theta inhibition impairs tumor growth and amplifies melphalan-induced DNA damage in multiple myeloma.
Journal: Journal of translational medicine
Published: July 08, 2025
Methionine Dependency and Restriction in Cancer: Exploring the Pathogenic Function and Therapeutic Potential.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: March 24, 2025
Macrophage migration inhibitory factor as a prognostic biomarker in multiple myeloma: clinical significance and in vitro effects.
Journal: Carcinogenesis
Published: March 01, 2025
LDHAL6B is a novel prognostic marker and promotes disease progression in multiple myeloma.
Journal: Haematologica
Published: October 24, 2024
Clonal Hematopoietic Mutations in Plasma Cell Disorders: Clinical Subgroups and Shared Pathogenesis.
Clonal Hematopoietic Mutations in Plasma Cell Disorders: Clinical Subgroups and Shared Pathogenesis.
Journal: Genomics, proteomics & bioinformatics
Published: January 09, 2024
Class II ferroptosis inducers are a novel therapeutic approach for t(4;14)-positive multiple myeloma.
Journal: Blood advances
Published: December 13, 2023
FTO promotes multiple myeloma progression by posttranscriptional activation of HSF1 in an m6A-YTHDF2-dependent manner.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: June 09, 2021
Showing 1-12 of 12
Last Updated: 09/26/2026